Apixaban (Eliquis) is a new experimental oral anticoagulant that acts as a direct factor Xa inhibitor. It will be in direct competition with warfarin (Coumadin) for the prevention of stoke in patients with atrial fibrillation. In a recent head to head comparison study with warfarin, it has shown non-inferiority, superiority, improved stroke prevention, and improved mortality. As a result of these findings, apixaban has generated excitement at the current European Society of Cardiology meeting.
See the Medpage Today interview with Dr. Elliot Antman, from Harvard Medical School, regarding the apixaban study results:
Reference: ESC: Apixaban May Be the Real Thing